TECH
LONGINSIDER SELLBIO-TECHNE CORP
Research: Finviz ↗·Perplexity ↗
🗄 Viewing archived Q1 2026 data — frozen, no longer refreshed.
News Summary
NeutralBio-Techne reported Q3 FY2026 results with a modest EPS miss (-1.85%) and revenue miss (-1.49%), driven by weakness in early-stage biotech spending despite strength in cell/gene therapy and large pharma. The headline development is Merck KGaA's acquisition announcement on June 25, 2026, at $73/share (36% premium), expected to close by late 2026/early 2027 with €140M in cost synergies, effectively ending Bio-Techne as an independent public company.
Red flags
- •Q3 EPS missed consensus by 1.85% ($0.53 vs $0.54 forecast)
- •Q3 revenue missed consensus by 1.49% ($311.4M vs $316.12M forecast)
- •Organic revenue declined 2% YoY, with adjusted gross margin down 120 bps YoY
- •Early-stage biotech demand remains weak despite strong funding environment
- •Stock tumbled 16.4% on May 6 post-earnings
- •Fiscal 2026 EPS forecast declined 3.5% YoY to $1.65; FY2027 guidance relies on uncertain biotech stabilization
Funds Buying (3)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Maverick Capital | Lee Ainslie | 4.7M | +889K | $248M | 2.9% | +23% | Existing |
| Durable Capital Partners | Henry Ellenbogen | 4.5M | +2.4M | $233M | 2.4% | +113% | Existing |
| Point72 | Steve Cohen | 295K | +295K | $15M | <0.1% | — | NEW |
Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.
Portfolio Context
Where TECH ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.
position #12 of this fund's book
- 9BOSTON SCIENTIFIC CORP$263M
- 10ARGAN INC$253M
- 11ALPHABET INC$250M
- 12BIO-TECHNE CORP$248M
- 13VISA INC$244M
- 14NATERA INC$234M
- 15CAPITAL ONE FINL CORP$228M
position #20 of this fund's book
- 17PRIVIA HEALTH GROUP INC$249M
- 18COUPANG INC$243M
- 19OPTION CARE HEALTH INC$242M
- 20BIO-TECHNE CORP$233M
- 21WIX COM LTD$184M
- 22CRH PLC$155M
- 23CLEAR SECURE INC$144M
Values are quarter-end position sizes. Shown only for funds where TECH ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.
Signal History
| Quarter | Direction | Funds | Score | vs SPY |
|---|---|---|---|---|
| Q2 2026 | SHORT | 4 | 3.88 | +0.2% |
| Q1 2026 | LONG | 3 | 3.85 | +19.1% |
Same issuer appearing in consecutive quarters — persistent institutional conviction. Returns are frozen at each archived quarter's last refresh.
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed | Src |
|---|---|---|---|---|---|---|---|
| Herr Amy E. | — | SELL | 7K | $48.28 | $0.32M | 2026-05-08 | ↗ |